Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)
Study sponsor: Mirum Pharmaceuticals, Inc. · MIRM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-07-13Actual
Enrollment · participants19Actual
Source updated2024-10-28Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.